Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339910 · ClinicalTrials.gov registry record · Phase 3
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
A Phase 3 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
NCT01339910: Clinical Trial Phase 3 study, sponsored by Medical College of Wisconsin.
NCT01339910 is a Phase 3 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 272 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01339910, a Phase 3 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
Study Summary
The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients receiving myeloablative conditioning (MAC) versus reduced intensity conditioning (RIC) regimens.
Primary Outcome
Overall survival is defined as survival of death from any cause.
Interventions
- DRUG Fludarabine and Busulfan
- DRUG Fludarabine and Melphalan
- DRUG Busulfan and Fludarabine
- DRUG Cyclophosphamide and Total Body Irradiation
- DRUG Busulfan and Cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2011-06 |
| Est. Completion | 2017-10-16 |
| Phase | Phase 3 |
Why NCT01339910 stopped before completion
NCT01339910 is an interventional study that assigns participants to a tested intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 5 interventions - of which Fludarabine and Busulfan is the first listed.
NCT01339910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01339910 about?
NCT01339910 is a clinical study titled "Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)". The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients receiving myeloablative conditioning (MAC) versus reduced intensity conditioni...
What is the current status of trial NCT01339910?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2011-06. Estimated completion is 2017-10-16.
What interventions are being tested in trial NCT01339910?
The interventions under investigation include: Fludarabine and Busulfan (DRUG), Fludarabine and Melphalan (DRUG), Busulfan and Fludarabine (DRUG), Cyclophosphamide and Total Body Irradiation (DRUG), Busulfan and Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT01339910?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01339910's enrollment target sits among peer trials
272 1214th of 2000 higher than 785 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
- NCT06083051 · 272 participants · NA
Differences in Postoperative Symptoms With Four Ureteral Stents
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia